Chitosan applications on pharmaceutical sciences: A review by Briones Nieva, Cintia Alejandra et al.
Send Orders for Reprints to reprints@benthamscience.net 
 Drug Delivery Letters, 2019, 9, 000-000 1 
REVIEW ARTICLE 
 2210-3031/19 $58.00+.00 © 2019 Bentham Science Publishers  
Chitosan Applications on Pharmaceutical Sciences: A Review 
Cintia Alejandra Briones Nieva, Mercedes Villegas, Alicia Graciela Cid, Analía Irma Romero and José María 
Bermúdez* 
Instituto de Investigaciones para la Industria Química, Universidad Nacional de Salta - Consejo Nacional de 
Investigaciones Científicas y Técnicas, Av. Bolivia 5150, Salta Capital (4400), Argentina; Facultad de Ingeniería, 
Universidad Nacional de Salta, Av. Bolivia 5150, Salta Capital (4400), Argentina 
 
A R T I C L E  H I S T O R Y 
 
 
Received: December 21, 2018 
Revised: March 01, 2019 








Abstract: Background: Chitosan (CS) is a biomaterial derived from chitin, known for its excellent bio-
logical properties. One of the most interesting features of CS is its potential for chemical derivatization, 
which makes it a versatile material and allows to expand its applications.  In the last years, the  
interest on this polymer and its pharmaceutical applications has notably increased. This biopolymer is  
being widely studied for its interesting properties, such as bioadhesion, antimicrobial activity, biocom-
patibility, and biodegradability. Other promising properties of CS include its modulation of immu-
nological response, hemostasis, and wound and bone healing activity. 
Objective: In this work, a critical review is performed covering its conventional and novel applications, 
specially focused on pharmaceutical area, providing a clear picture of the current state of art to serve as 
a basis to direct future research in this field. 
Conclusion: Despite all the qualities of this polymer, there are only few CS-based products in the mar-
ket, so it is a priority to enhance the research to develop new technologies and CS-based systems to en-
force this biopolymer in the industry.  
Keywords: Biomaterials, pharmaceutical applications, biodegradable, biocompatible, drug delivery/release, gene therapy.  
1. INTRODUCTION 
 A biomaterial is defined as any material or combination 
of materials, of natural or synthetic origin, designed to inter-
act with the biological systems in order to evaluate, treat or 
replace some tissue or organ of living beings [1]. Biomateri-
als can be classified as natural or synthetic. The former, such 
as purified collagen and protein fibers, are complex, hetero-
geneous materials, and, in some cases, more difficult to 
characterize and process. Synthetics can be metals, ceramics 
or polymers, and are commonly known as biomedical mate-
rials, to differentiate them from those of natural origin [2]. 
 In recent years, several biomaterials have been studied 
not only for medical and pharmaceutical uses, but also for 
agricultural and biotechnological purposes since they do not 
have toxic effects on the environment [3]. Within biomedical 
materials, biopolymers have particularly found several appli-
cations in the biomedical field. For example, alginate, chito-
san (CS) and gelatin are being studied in regenerative medi-
cine. Among the biopolymers, carbohydrate polymers have 
had a great impact in therapeutic, pharmaceutical and bio-
medical applications. Within this category, polysaccharides  
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are one of the most abundant industrial raw materials, which 
have been the subject of intense research due to their biode-
gradability, biocompatibility, sustainability and biosafety. 
The second most abundant polysaccharide in nature after 
cellulose is chitin, from which CS is obtained (Fig. 1). Chitin 
is a white, hard, inelastic linear polymeric carbohydrate, 
composed of repeating units of N-acetyl-D-glucosamine and 
it is found in the exoskeleton of crustaceans, in the internal 
structure of invertebrates and in fungal cell walls.   
 Despite CS favorable biological and structural properties, 
its extensive use in biomedical applications is limited by its 
insolubility in water and in common organic solvents [4]. 
Nevertheless, in the last decade, remarkable advances have 
been made in CS and its derivatives, demonstrating their 
wide applications in the biomedical field. They have been 
exploited in the manufacture of immediate-release tablets, 
where they can act as a disintegrant [5] or as a binder [6], 
depending on the degree of deacetylation (DD) and the con-
centration employed in the formulation.   
 CS is also promising due to the presence of a large num-
ber of hydroxyl and amino groups, through which, it can be 
modified by various chemical reactions to prepare a series of 
CS derivatives as non-toxic biocompatible biomaterials [7]. 
An intensive research has been carried out to demonstrate the 
safety of the polymer and its ability to activate wound  
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healing and tissue repair. Furthermore, CS is generally rec-
ognized as safe [8] by the FDA for wound applications [9] 
and it has a well-characterized biocompatibility profile, 
which makes it a promising biopolymer for use in implanted 
devices and for drug delivery [10, 11]. In fact, the develop-
ment of commercial products in the form of wound dressings  
constitutes one of the most consolidated applications of this 
polymer in clinical practice (Table 1) [12-14]. 
 Drugs such as antibiotics or antimicrobials may be mixed 
directly into viscous CS solutions which can then be used to 
develop films, beads, gels or other drug delivery devices 
[15]. Due to its positive charge, this polymer can interact 
with excipients and/or drugs with negative charge. This in-
teraction has been intensively explored to modulate the re-
lease rate of low and high molecular weight (MW) drugs 
[16]. In the latter case, CS has been a powerful tool, allowing 
the administration of therapeutic proteins [17], vaccines [18], 
and DNA [19]. However, post-processing steps, that usually 
involve neutralization, cross-linking, rinsing, etc., can lead to 
the loss of the incorporated drug or drug activity.  
 Due to its excellent and unique biological properties (Fig. 
2), CS is generally used as an antibacterial, antifungal and 
adhesive agent, either alone or blended with other polymers 
[4]. In fact, CS commercial applications are based on its an-
timicrobial and bio-stimulating properties. CS antimicrobial 
activity has been recognized for more than 30 years, al-
though its precise mechanism of action remains unknown 
[20]. Probably, it is related to CS polycationic structure, 
since when the pH of the environment is below its pKa, elec-
trostatic interactions can occur between its polycationic 
structure and lipopolysaccharides and/or proteins in the sur-
face of microorganisms, leading to the leakage of intracellu-
 
Fig. (1). Preparation of chitosan by the deacetylation of chitin. 
 
Table 1. Some commercially available wound CS-based products. 
Commercial Name Active Components Presentations 
HemCon® Chitosan acetate Patch, bandage, gauze 
ChitoFlex® Chitosan acetate Roll, strip 
TraumaStat® Chitosan Bandage 
Chitopack C® Chitosan acetate Nonwoven dressing 
Tegasorb™ Chitosan Films 
 
 
Fig. (2). Properties of chitosan. 
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lar constituents [21]. Then, the antimicrobial activity is 
strongly influenced by the pH of the medium, but it also de-
pends on CS MW and DD, and on the nature of the organism. 
In general, molds and yeasts are the most sensitive, followed 
by Gram-positive and Gram-negative bacteria [22]. As can 
be seen, CS has functional groups sensitive to the conditions 
of the surrounding environment, such as temperature, pH, 
ionic strength, magnetic field, and ultraviolet light. These 
materials, commonly referred to as "smart materials” or 
“stimuli response materials”, have promising applications in 
the area of drug delivery and wound healing. 
 Figs. (3 and 4) show the growing interest in CS repre-
sented by the number of scientific articles on "chitosan & 
biomedical applications" and "chitosan & drug delivery", 
respectively, in the most recognized scientific publications 
databases available on the web, such as Science Direct, 








Fig. (4). Number of publications per year found with the keywords "chitosan & drug delivery" in scientific publications databases. 
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Fig. (5). Chitin and CS production by chemical and biotechnological treatments. 
 In this work, a critical review is performed covering CS 
conventional and novel applications, specially focused on the 
pharmaceutical area, providing a clear picture of the current 
state of the art to serve as a basis to direct future research in 
this field. 
2. CS PRODUCTION AND MODIFICATIONS 
 CS is commercially obtained by deacetylating chitin, 
which is extracted either from crustacean shells via chemical 
and/or enzymatic procedures, or from mycelia obtained from 
fungal. Crab, shrimp, and prawn shells are the main raw ma-
terial for chitin extraction, after which demineralization and 
deproteinization steps are required, followed by a 
deacetylation stage to transform the chitin into CS (Fig. 5). 
There are different alternatives to carry out these steps, in-
cluding chemical and enzymatic procedures. Since the for-
mer involves the use of strong alkali and acids, they present 
some disadvantages, such as the polymer hydrolysis, the lack 
of reproducibility of the final physiological properties, and 
environmental pollution, making it necessary to further neu-
tralize and detoxify the wastewater [23]. The replacement of 
one or several stages by biotechnological methods, including 
the use of enzymes, avoids some of these drawbacks, how-
ever, there are also some disadvantages associated with this 
technology, such as high residual protein, longer reaction 
times and high costs of enzymes, limiting the enzymatic 
methods for industrial applications [24]. One of the most 
developed alternatives in this sense is the raw material diges-
tion with proteolytic enzymes such as papain, pepsin, tryp-
sin, and pronase, during the deproteinization stage. 
 Once the chitosan is obtained, it can be further processed 
in order to grant certain characteristics. Fig. (6) summarizes 
some techniques used for the modification of CS, which in-
clude physical, chemical and electro-physical methods.  
 Among the possible physical modifications, cryo-milling 
is an effective method to produce micro-sized or even nano-
sized particles increasing their surface volume ratio [25].  
However, one of the most interesting features of CS is its 
potential for chemical derivatization, which makes it a versa-
tile material and allows to improve its solubility and to ex-
pand its applications. The hydroxyl groups at C(6) and C(3) 
positions and the amino or amido groups at C(2) positions 
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provide functional sites for specific modifications. Different 
chemical modifications were explored to prepare CS deriva-
tives for biomedical applications, including deacetylation, N-
acetylation and other acylation reactions, Schiff’s base for-
mation, N-phthaloylation, N-carboxyalkylation, N,O-
carboxymethylation, and graft copolymerization. Although 
CS chemical modification alters its properties, it is possible 
to preserve some important characteristics such as its bio-
compatibility, mucoadhesivity and biodegradability [26]. 
Chemical modification is a powerful tool to enhance drug 
load capability, to control polymer-drug interaction, and to 
improve CS bulk properties to prepare sustained drug release 
systems. The hydroxyl and amine groups of CS allow to at-
tach CS coatings to different materials as well as to form 
antimicrobial derivatives [27]. Moreover, the antioxidant 
activity of CS and its derivatives is attributed to its ability to 
easily abstract hydrogen atoms from free radicals. The 
chemical modification of CS to produce new bio-functional 
materials has been successfully achieved [28]. Crosslinking 
is another method that can be employed to modify CS to 
change its hydrophilicity [29] or to increase its mechanical 
strength [30].  
 Finally, an interesting alternative to modify CS involves 
the use of electro-physical procedures. In this regard, Radio 
Frequency (RF) rotating plasma, ion beam, solution plasma 
process, among others, offer some advantages over chemical 
methods such as oxidation, derivatization and crosslinking, 
since they are safe and clean processes [31], and avoid risks 
associated with chemical wastes. 
3. USE OF CS AND DERIVATIVES IN CONVEN-
TIONAL PHARMACEUTICAL FORMULATIONS 
FOR BIOMEDICAL APPLICATIONS 
 The existence of amino groups in the deacetylated CS 
provides functional binding sites to react with drugs, modu-
lating the release profile of the active agent due to physical 
interactions [32-34]. Moreover, the biodegradability of CS is 
a very valuable property for designing drug delivery systems 
since surgical removal is not necessary after the therapeutic 
action has been completed [35]. On the other hand, the 
rheological properties of CS polymers also allow their use as 
an excipient, either as a binder or as a coating material in 
tablets [16]. In addition, the cationic charge of CS and the 
hydrogen bonding interactions give it mucoadhesive proper-
ties, which allow its adhesion to the mucin molecules that are 
found in the mucosal layer covering the epithelial tissues 
[36]. All these CS properties explain its wide range of appli-
cations. 
3.1. Oral Administration 
 The oral route is the most frequently used in drug  
delivery for both conventional and novel drugs, due to the 
ease of administration and general acceptance by patients. 
However, the bioavailability of drugs after oral administra-
tion is very low, mainly because of their instability in the 
gastrointestinal (GI) tract, caused by the presence of pepti-
dases and the strong acid pH in the stomach. In addition, a 
low permeability through the intestinal mucosa, in the case of 
drugs with high MW and/or hydrophilicity, will also con-
tribute to low bioavailability. Controlled drug release sys-
tems for oral administration are generally based on polymers, 
and release mechanisms usually depend on the phenomena 
of diffusion, bioerosion or degradation, and swelling or gen-
eration of osmotic pressure. Diffusion process occurs when 
the drug-polymer system is exposed to the GI fluid, which 
causes the release of the drug from the polymeric carrier 
system to the surrounding medium. Depending on the com-
position of the drug-polymer complex, the phenomenon of 
bioerosion or degradation can occur in certain sections of the 
GI tract. The swelling phenomenon occurs mainly with 
polymers called polyelectrolytes when they are exposed to 
the GI fluid, which produces a modulated drug release, con-
trolled by the material swelling rate.  
 The solubility of CS in an acidic environment can be 
exploited to develop coatings for advanced systems that  
respond to stimuli or are targeted to specific tissues. For  
example, a drug capsule can be coated with CS to prevent  
 
Fig. (6). CS modification techniques. 
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degradation at high pH until it reaches an acidic environ-
ment, such as in the stomach.  
 An interesting work was conducted by Gonçalves et al. 
[37], who used CS as a mucoadhesive coating on alginate 
beads loaded with amoxicillin. These beads exhibited excel-
lent encapsulation efficiency, high drug loading capacity, 
and a strong in vitro mucoadhesion to the gastric mucosal 
layer. In the same regard, Wang et al. [38] formulated free 
liposomes of CS-coated cholesterol to encapsulate proges-
terone, based on the structurally similar properties of proges-
terone and cholesterol. The results obtained allowed them to 
conclude that CS-coated liposomes are a promising alterna-
tive to improve the oral bioavailability of progesterone.  
 In another interesting approach, Ubaid et al. [39] pre-
pared an optimized CS/gelatin pH-sensitive hydrogel using 
different concentrations of genipin as a crosslinking agent 
for the oral delivery of metformin. It was observed that the 
release rate profile could be modulated according to the con-
centration of the crosslinking agent. 
3.2. Buccal Mucosa Administration 
 Drug administration through the buccal mucosa in the 
mouth provides unique advantages, such as avoiding the 
hepatic first-pass metabolism, and the acidity and proteolytic 
activity of the rest of the GI tract [40]. Buccal absorption of a 
non-ionized drug depends on its solubility in lipids, as well 
as on the pH of the saliva and the partition coefficient of the 
drug, which indicates its relative affinity for the vehicle and 
for the epithelial membrane. An ideal system for the buccal 
administration of drugs should comply with certain parame-
ters, such as the ability to remain in the oral cavity for a few 
hours while releasing the drug unidirectionally towards the 
mucosa at a controlled or sustained rate. The drug delivery 
systems designed for buccal administration can be applied in 
the treatment of various diseases, like periodontitis, stomati-
tis, fungal and viral infections, and cancers of the oral cavity. 
Due to its muco/bioadhesive qualities, CS is an excellent 
candidate to transport buccal drugs, acting also as an absorp-
tion enhancer. In this regard, Freag et al. [41] evaluated the 
mucoadhesive properties of CS-based composite sponges 
with five different polymers: Carbopol®, sodium car-
boxymethylcellulose, hydroxypropylmethylcellulose, sodium 
alginate and hyaluronic acid. The formulations were pre-
pared by adding each selected dissolved polymer in a CS 
hydrogel at different CS:polymer ratios, and then lyophi-
lized. The authors concluded that all proposed composite 
sponges showed a percentage of moisture content and sur-
face pH values within acceptable ranges. Moreover, among 
all the composite sponges, CS: hydroxypropylmethylcellu-
lose (1:1) ones significantly enhanced the mucoadhesion 
time and showed the best physicochemical characteristics for 
buccal applications. Another study was conducted by Portero 
et al. [42], who developed a bilayered flexible device for the 
administration of insulin by casting/freeze-drying procedure, 
consisting in a mucoadhesive CS layer containing the pep-
tide drug and an impermeable protective layer made of 
ethylcellulose. Three different salts of CS were compared: 
CS glutamate, CS tartrate and CS citrate. Authors found that 
the swelling properties of the sponges made from the diffe-
rent salts of CS were different and that the type of acid used 
to dissolve CS influenced insulin release from the sponges. 
They concluded that the affinity of chitosan sponges to 
mucin surfaces was related to the swelling and solubility 
properties of the different salts of chitosan.  
 Recently, Tejada et al. [43] described the formulation of 
miconazole nitrate buccal films and found that those formu-
lated with CS-hydroxypropylmethylcellulose were the most 
appropriate due to their resistance to folding and their me-
chanical and mucoadhesive properties. In vitro antifungal 
activity assays showed a significant activity of the model 
drug used in the films. 
3.3. Gastro-retentive Delivery 
 The gastro-retentive drug delivery systems are designed 
to increase the retention time in the stomach of a dosage 
form administered orally, representing an advantageous 
technological alternative for drugs that are absorbed in the 
GI tract, for drugs with limited solubility in the alkaline me-
dium and also for drugs that are intended to produce a loca-
lized effect on the gastroduodenal wall [44]. They would be 
especially useful for drugs with limited solubility in the in-
testinal fluid and which are also highly soluble at acidic pH. 
CS is a promising polymer for the development of gastro-
retentive drug delivery systems because it combines the 
properties of bioadhesion and flotation capacity [45]. CS 
could be ideal for the development of systems designed to 
release drugs at a slow rate in the stomach, due to the forma-
tion of a hydrogel, which will cause a delaying effect in the 
process of drug release. 
 In vitro and in vivo evaluation of gastro-retentive CS 
beads loaded with carvedilol were carried out by Praveen et 
al. [46]. The beads were found to have a plausibly and ex-
tended absorption due to the buoyant nature of the device in 
comparison with drug suspensions. On the other hand, in 
silico study indicated a maximum absorption from the duo-
denum (94.1%) followed by jejunum. All these results al-
lowed the authors to conclude that CS beads could be a po-
tential drug carrier of carvedilol with improved bioavailabil-
ity. 
 Kim et al. [47] designed bacteriophages belonging to 
the Myoviridae family encapsulated into CS–alginate micro-
spheres to evaluate their acid stability, release property and 
antimicrobial efficacy against Escherichia coli under simu-
lated GI conditions. They found that the bacteriophages were 
stable at pH values above 4, but the CS-­‐alginate microsphere 
exhibited a protective effect on the bacteriophages in the 
simulated gastric (pH 2) conditions. Moreover, the encapsu-
lated bacteriophages maintained the lytic efficacy against E. 
coli in the simulated intestinal conditions for 10 h of incuba-
tion, suggesting that these microspheres could be used as a 
reliable delivery system for bacteriophages. 
3.4. Colon-specific Drug Delivery 
 Drug delivery systems directed to the colon have been 
widely studied in the last two decades. Although oral absorp-
tion occurs mainly in the small intestine, the residence time 
of the ingested materials in the colon is much higher. The 
peristaltic movements cause the food to pass through the 
small intestine in a few hours, but it can remain in the colon 
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for up to 3 days. The colonic administration of drugs has 
several therapeutic advantages over the oral administration 
of drugs, wherein the drugs can be destroyed by stomach 
acid and/or metabolized by pancreatic enzymes. In this con-
text, CS is widely used for the administration of colon-
specific drugs, due to its high solubility in acidic stomach 
fluids, being degraded in the colon, like other polysaccha-
rides. Although eventually, CS can become insoluble in an 
acidic environment by chemical crosslinking, what would be 
desired for a colon drug delivery system, this modified 
polymer is ineffective in preventing the release of the encap-
sulated drugs. 
 Drechsler et al. [33] developed film-coated tablets con-
taining the model drug diclofenac-Na. The tablets consisted 
of a core of the drug and microcrystalline cellulose (MT), or 
Ludiflash® (LT), and were coated with CS alone or different 
ratios of CS and Kollicoat (KCSS). CS/KCSS (25:75) coated 
LTs showed a pressure-controlled site-specific drug release 
in the large intestine while remaining intact in the upper GI 
tract. CS as well as CS/KCSS (25:75) applied onto MTs, 
remained stable during the entire simulated bio-relevant dis-
solution transit of the GI tract, but showed enzymatically 
controlled colon targeting in the colon microflora test. This 
result was confirmed for CS/KCSS (25:75) applied onto 
MTs with an additional hydroxypropylmethylcellulose layer 
and a Eudragit® layer to avoid the dissolution in the fasting 
stomach. 
3.5. Vaginal-specific Drug Delivery 
 The current research on vaginal drug delivery is focused 
on the systemic delivery of drugs such as some hormones 
and prostaglandins. New technologies are evaluating the 
feasibility of providing therapeutic peptides and proteins 
through the vaginal route to achieve a systemic effect. The 
volume of fluid within the vaginal cavity is relatively small. 
For this reason, probably the limiting step in the process of 
systemic absorption of drugs transported in creams, inserts 
and intravaginal tablets is the rate of dissolution in the vagi-
nal fluid. This is much more evident for drugs with limited 
solubility. In addition to the physicochemical factors associa-
ted with the drug, the stability of the drug in vaginal fluids is 
particularly important. Furthermore, labile drugs may un-
dergo enzymatic deactivation before absorption.  
 Abruzzo et al. [48] prepared freeze-dried vaginal inserts 
of CS/alginate at different polycation/polyanion molar ratios 
and loaded with chlorhexidine digluconate for local delivery 
in genital infections. In vitro water-uptake, mucoadhesion 
and release tests showed that a suitable CS/alginate molar 
ratio and drug loading allowed to modulate the insert ability 
to hydrate, adhere to the mucosa, and release chlorhexidine 
digluconate. On the other hand, authors found that the insert 
containing an excess of alginate had the best performance 
and antimicrobial activity against the pathogens Candida 
albicans and E. coli. Other interesting research was con-
ducted by Marciello et al. [49], who developed sponge-like 
systems consisting of CS nanoparticles (NPs) loaded with 
the model peptide insulin using mannitol, sucrose, gelatin B 
and polyethylene glycol (PEG) stearate as excipients. The 
objective of this study was to facilitate the in situ application 
and quickly dissolution in the vaginal environment, releasing 
the peptide-loaded NPs. In vitro and ex vivo experiments 
indicated that the designed systems were able to promote the 
peptide release and penetration into vaginal mucosa. On the 
other hand, the cylinders based on mannitol/sucrose and 
gelatin showed the best mechanical resistance properties for 
their application and storage. 
3.6. Nasal Administration 
 Due to the high vascularization of the nasal mucosa and 
the possibility of avoiding the first hepatic passage, added to 
the ease of administration, the nasal route represents an in-
teresting alternative for the recurrent administration of some 
drugs. The advance of biotechnology has increased the  
availability of proteins and peptides (for example, insulin, 
growth hormone, etc.), leading to growing research and de-
velopment of innovative intranasal drug delivery systems 
[18]. Among the latest advances, mucosal vaccines for nasal 
administration stand out. CS has been used not only as an 
excipient in the formulation but also as a promoter of the 
absorption of therapeutic proteins administered nasally. It 
has been proved that the joint administration of CS and anti-
gens in the nasal cavity produces an improvement of the sys-
temic and also of the mucosal immune responses. Unlike 
oral administration, vaccines administered by the nasal route 
must be transported for short distances, in addition to not 
being exposed to low pH values and degrading enzymes. For 
this reason, it is not necessary to incorporate the vaccine  
into microparticles when administered nasally. Thus, CS  
particles, powders, and solutions are promising candidates 
for mucosal and nasal vaccine delivery. In this regard,  
Dabaghian et al. [50] evaluated a nasal vaccination with 
r4M2e.HSP70c influenza antigen encapsulated into N-
trimethyl CS (TMC) nanoparticulate systems. The results 
showed that intranasal immunization of mice with TMC NPs 
significantly increased the longevity and serum level of the 
total M2e-specific IgG antibody compared to the control 
groups. 
 When a rapid onset of action is required, the CS-based 
technology for nasal administration can provide a rapid 
maximum concentration, compared to oral or subcutaneous 
administration. The combination of bioadhesion and the 
opening of tight junctions between epithelial cells play a 
major role in CS-based mucosal delivery [51]. 
 An interesting work was done by Luppi et al. [52], who 
developed a CS/pectin based nasal insert to improve the 
bioavailability of antipsychotic drugs. These polyelectrolyte 
complexes were prepared with different molar ratios of  
polycation/polyanion and lyophilized in small inserts in the 
presence of chlorpromazine hydrochloride. The results 
showed that a greater amount of pectin in the complexes 
produced a more evident porous structure of the nasal  
inserts, improving water uptake ability and mucoadhesion 
capacity, but the interaction between pectin and 
chlorpromazine-induced the formation of less hydratable 
inserts, limiting drug release and permeation.  
3.7. Pulmonary Delivery 
 Since the mid-twentieth century, aerosols have been used 
in different ways for the treatment of respiratory disorders. 
However, interest in the pulmonary route for the systemic 
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administration of drugs is relatively recent. The potential of 
this route for the administration of peptides and its viability 
for the treatment by gene therapy of cystic fibrosis have mo-
tivated researchers remarkably. The administration of drugs 
based on the inhalation is a practical and non-invasive way 
to administer therapeutic agents, including genes, to the 
lungs. However, a study found that CS microparticles used 
for inhalation induced dose-­‐dependent proinflammatory  
effects in rat lungs [53]. In this sense, Zhang et al. [54] per-
formed in vivo implantation experiments of theophyl-
line/carboxymethyl CS/β-­‐cyclodextrin microspheres, foun-
ding that the inflammatory reaction gradually lessened and 
disappeared and had no significant difference from that of an 
operative suture. Manca et al. [55] developed new liposomes 
coated with CS–xanthan gum as potential carriers for pul-
monary delivery of rifampicin. Results indicated that nebuli-
zation and rheological properties of coated liposomes were 
affected by the CS–xanthan gum weight ratio. Another  
interesting approach was conducted by Oyarzun-Ampuero  
et al. [56], who prepared mucoadhesive nanocarriers based 
on CS and hyaluronic acid, loaded with heparin. The nano-
carriers presented a high drug loading efficiency (about 
70%) and high stability in phosphate-buffered saline. 
Moreover, ex vivo experiments indicated that these nanocar-
riers could be used for effective pulmonary delivery systems. 
3.8. Transdermal Administration 
 Transdermal drug delivery systems have been widely 
used to release drugs through the skin and represent a  
valuable alternative to conventional routes of administration, 
such as oral, intravascular, subcutaneous and transmucosal. 
Many drugs have inherent side effects that cannot be avoided 
under any form of dosage. However, there are drugs that 
manifest undesirable effects that are specifically related to a 
particular route of administration. Different technological 
strategies are being used to avoid some of the problems re-
lated to traditional dosage forms, and one of the most prom-
ising is the development of transdermal drug delivery sys-
tems. In this regard, the development of a suitable formula-
tion is essential to provide adequate and reproducible drug 
release rates. The components of the formulation will deter-
mine the rate of release of the drug in the skin and also in the 
substrate used for the adherence of the device to the skin, 
which will, therefore, influence the performance of the final 
product.  
 Anirudhan et al. [57] developed an efficient device based 
on CS and hyaluronic acid for the administration of trans-
dermal lidocaine. The results indicated that this device had a 
good skin adhesion and did not irritate the skin even after 24 
h of application. In addition, it was resistant to microbial 
activity and was suitable for long-term drug delivery.  
 Due to their unique properties, nanofibers have been 
studied in transdermal drug delivery systems, as they could 
provide constant blood levels over a longer period and avoid 
first pass metabolism. Cui et al. [58] evaluated electrospun 
fibers of cross-linked polyvinyl alcohol/CS (PVA/CS) 
loaded with ampicillin sodium for transdermal drug delivery. 
It was observed that the cross-linked PVA/CS composite 
nanofibers had lower drug release rate and a smaller amount 
of drug burst release than that of PVA/CS (without 
crosslinking). 
3.9. Ophthalmic Drug Delivery 
 The ocular route for drug administration is used only for 
the local treatment of eye conditions and it is not viable to 
use it for the systemic administration of drugs. The efforts in 
the ocular administration of drugs have been oriented to im-
prove the corneal penetration and the residence time of drugs 
in the eye, in order to increase the effectiveness of the treat-
ments of different ocular diseases. The attempts include the 
use of colloidal drug delivery systems, such as liposomes, 
biodegradable NPs, and nanocapsules [59]. It should be 
noted that the short residence time of these colloidal formu-
lations in the ocular mucosa is the main limitation in the 
treatment of extraocular diseases, such as keratoconjunctivi-
tis sicca, or dry eye disease [59]. On the other hand, remar-
kable advances have been made in recent years to optimize 
the localized supply of drugs in the eye. In this way, the ocu-
lar route is now associated with the application of drug de-
livery technologies with a high level of sophistication. Some 
of these technologies are unique to the eye pathway and 
many of them are also used in other drug delivery routes. 
From the ocular point of view, the physicochemical proper-
ties of CS show a pronounced effect on drug stability within 
the ocular bioenvironmental conditions [60, 61]. In addition, 
the positive charge and the bioadhesive nature of CS could 
allow increasing drug residence time in ocular tissues by 
ionic interaction with the negatively charged mucin residues 
located on the surface of the eye.  CS-based carrier systems 
have been developed for the delivery of many ocular thera-
peutic molecules including antibiotics, anti-inflammatory, 
anticholinergics, analgesics, proteins and peptides, and 
genes, among others [62]. 
 Natesan et al. [63] worked with CS NPs and PEG-
modified CS NPs co-encapsulated with resveratrol (RES) 
and quercetin (QUR). They evaluated the synergic effect on 
reducing the intraocular pressure for glaucoma treatment in 
tests performed with normotensive rabbits. Authors reported 
a sustained and enhanced reduction of the intraocular  
pressure for the PEG-modified CS NPs loaded with RES and 
QUR. On the other hand, Rodriguez et al. [64] prepared  
dexamethasone loaded CS films, that were tested as a topical 
ocular delivery dosage form. The authors determined that the 
release time was longer than for conventional systems,  
making it an interesting option as an ocular delivery carrier. 
4. ADVANCED APPLICATION OF CS AND DERIVA-
TIVES IN DRUG DELIVERY SYSTEMS 
 CS is a promising biopolymer with a high potential for 
applications in the biomedical field due to its versatility and 
ability to form different configurations, including films, 
beads, sponges, and gels. In addition, CS can be chemically 
modified to functionalize it and improve its performance in 
the area of medicine, especially in relation to the drug  
delivery, for example, to design antibiotic release systems 
for local or systemic use [65, 66]. CS can also bind to pro-
teins, DNA, and RNA [67, 68], which may be useful in treat-
ing or preventing infections through vaccines or gene thera-
py [69]. Other advantages of CS include modulation of im-
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munological response, hemostasis, wound and bone healing 
activity, and inherent antimicrobial activity [10]. 
 CS has been explored to form hydrogels for drug delivery 
because of its solubility in acidic solutions and its cationic 
charge in the protonated form [65]. Among the main advan-
tages of CS hydrogels used for local drug delivery, injecta-
bility, rapid degradation, and elimination can be mentioned, 
as well as the possibility of achieving a controlled release of 
drugs. On the other hand, CS-based hydrogels have the po-
tential to develop intelligent drug delivery systems, which 
respond to various stimuli, such as a change in pH or tem-
perature, among others. The mechanism of drug release from 
hydrogels is generally governed by the diffusion step, but it 
can also be modified by modulating the swelling process that 
will lead to the erosion of the hydrogel. 
4.1. Stimuli-sensitive CS -based Systems  
 In the biomedical area, special attention has been paid to 
the development of CS hydrogels sensitive to stimuli with 
biodegradability and biocompatibility qualities. An ideal 
drug delivery system that responds to different stimuli 
should be simple and inexpensive to manufacture, with the 
ability to deliver precise amounts of the drug in response to 
physiological or pathological stimuli. Polymeric hydrogels 
are defined as three-dimensional networks formed by trap-
ping water molecules in their structure producing the swel-
ling of the system. Due to their swelling properties, mem-
branes based on these hydrogels are usually highly per-
meable to hydrophilic or high molecular weight agents. This 
property, added to the biocompatibility and biodegradability, 
has motivated the development of hydrogels that act as 
membranes in devices to control the rate of protein release, 
such as insulin, aprotinin, tumor antigen factor, and  
luteinizing hormone. According to the previously mentioned, 
the so-called "intelligent hydrogels" are of great interest be-
cause they can manifest a reversible discontinuous phase 
change in response to various external physicochemical fac-
tors. Among the most feasible stimuli to be used in in vivo 
applications, those that respond to changes in temperature 
and pH stand out. 
4.1.1. pH-sensitive CS-based Systems 
 The chemical structure of CS and its derivatives shows 
that they contain hydroxyl and amino groups, and some of 
their derivatives can also have carboxyl or other functional 
groups. These ionizable groups are strongly influenced by 
the pH of the medium. For this reason, when an external pH 
change occurs, the dissociation equilibrium, the swelling 
characteristics and the interaction of CS and its derivatives 
with the solvents can be strongly modified [70]. Due to the 
unique characteristics of pH sensitivity, these systems have 
begun to find several applications in the biomedical and bio-
engineering fields, particularly as drug delivery carriers. 
Based on the CS own acidity, different CS-based systems 
have been prepared, including gels, interpenetrating polymer 
networks, NPs, and copolymers, among others, by adding 
different substances. 
 Du et al. [71] published a review article about CS-based 
pH-responsive nanoformulations for GI delivery. The 
authors have summarized different architectures and  
physicochemical properties used in pH-responsive systems 
for drug delivery in the GI tract. 
 Interestingly, Yilmaz et al. [72] have prepared CS-graft-
[poly(diethylamino)ethyl methacrylate] in three different 
physical forms, as linear free chains in solution, chemical 
gels crosslinked with glutaraldehyde, and 
poly(diethylamino)ethyl methacrylate grafted onto CS 
tripolyphosphate gel beads. They found that solubility of the 
products was controlled by the grafting yield. While pH-
sensitive polymers, which collapse at a given pH value, were 
obtained at lower grafting yields, hydrogels formed at higher 
grafting yields with pH-responsive swelling behavior. Glu-
taraldehyde crosslinked CS-graft-[poly(diethylamino)ethyl 
methacrylate] gels and CS tripolyphosphate gel beads grafted 
with poly[(diethylamino)ethyl methacrylate] exhibited pH-
sensitive swelling with highest equilibrium swelling capacity 
at a pH value of 1.2. 
4.1.2. Thermo-sensitive CS-based Systems 
 Thermo-sensitive polymers exhibit a temperature-
dependent phase transition in solution across a critical tem-
perature which is known as the critical solution temperature 
[70]. Copolymerization of CS or derivatives with some 
thermo-sensitive polymers, such as N-substituted polyacryl-
amides, methylcellulose, PVA, polyacrylic acid, poly-
vinylpyrrolidone, and polyethylene oxide, among others, can 
be used to produce new thermo-sensitive systems, which in 
turn have been used for obtaining copolymers, gels, beads, 
membranes, and NPs. Following this line, Li et al. [73] de-
veloped a thermo-sensitive injectable N-hexanoyl glycol CS  
hydrogel system for the percutaneous treatment of disc her-
niation to both restore the biomechanical function and reduce 
low back pain. The hydrogel showed a thermo-reversible sol-
gel transition at low concentrations (3-7 %wt). In vitro and in 
vivo tests reported no cytotoxicity nor adverse effects in a rat 
model. The hydrogel filling of the defective IVD site in an ex 
vivo porcine model maintained its stability for longer than 28 
days, suggesting that this material can be an alternative for 
the treatment of disk herniation. 
4.1.3. Photo-sensitive CS-based Systems 
 Photo-sensitive polymers undergo a macroscopic transi-
tion effect when submitted to irradiation. The introduction of 
photo-sensitizers in CS results in photo-sensitive polymers. 
In this regard, Jeong et al. [74] used water-soluble CS to 
fabricate chlorin e6 (Ce6)-incorporated nanophotosensitizers 
(ChitoCe6) via a self-assembling process. The photodynamic 
effect of ChitoCe6 was evaluated using GI cancer cells 
(SNU478 cholangiocarcinoma cells). The results showed that 
the particle accumulated effectively in the tumor tissue and 
inhibited tumor growth more than the treatment with Ce6 
alone. Furthermore, the nanophotosensitizer was also effi-
ciently absorbed through tissue layers in an ex vivo study 
using porcine bile duct explants. 
4.1.4. Electro-sensitive CS -based Systems 
 Polymers sensitive to electric field undergo various 
changes in macroscopic behavior, such as those induced by 
electric current. Since CS is a polycationic polymer, an elec-
trostatic interaction with polyacids or polyanions is possible. 
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It is known that an ion can move in the opposite direction to 
the application of an electric field. To confirm it, Goycoolea 
and Milkova [75] adsorbed CS with different MW and DD 
onto lecithin stabilized nanoemulsion droplets. They investi-
gated electrokinetic properties of the nanoemulsion by using 
dynamic light scattering, obtaining that the isoelectric point 
of the droplets in suspension in the presence of CS with op-
posite charge did not depend on the polyelectrolyte MW 
(when DD of CS was upper than 32%). On the other hand, 
the stability behavior of the nanoemulsion in the presence of 
CS with lower charge density was different, and the isoelec-
tric point and stabilization of the system were achieved at 
higher polymer concentration, agreeing with the notion that 
the electrostatic interactions were predominant in the coating 
layer formation. 
4.1.5. Magneto-sensitive CS -based Systems 
 Magneto-sensitive systems are typically composed of 
magnetic cores such as Fe2O3 or Fe3O4, and polymeric shells, 
thus presenting a strong magnetic response in the presence of 
an external magnetic field [70]. As drug delivery carriers, 
these systems could be transferred to the therapeutic site by 
applying a magnetic field where they can also exhibit sig-
nificant heating effects. On the other hand, drug-loaded 
magnetic NPs could be used to selectively accumulate the 
drug at the target site by an external magnetic field and, 
therefore, reduce the doses necessary to achieve the thera-
peutic concentration. In this context, Natesan et al. [76] pre-
pared magnetic NPs of artemisinin using CS by the ionic-
gelation method for the treatment of breast cancer. The NPs 
were smooth and spherical in nature and their size was in the 
range of 349–445 nm. They showed 55% to 62.5% of drug 
encapsulation efficiency and 20% to 25% drug loading ca-
pacity. Around 62% to 78% of artemisinin was released from 
the artemisinin magnetic NPs over the period of 48 h. Fi-
nally, on the application of physiologically acceptable exter-
nal magnetic field, FITC conjugated artemisinin magnetic 
NPs showed an enhanced accumulation of NPs in the 4T1 
breast tumour tissues of BALB/c mice model. 
4.2. CS-based Nanodelivery Systems 
 The trend of micronizing carrier polymer particles began 
before the introduction of nanotechnology into drug delivery 
systems. NPs have a size of 100 nm or less and are being 
used intensively in innovative commercial products, inclu-
ding the development of nanotechnological platforms for 
medicinal applications. The applicability of NPs for use in 
drug delivery depends on many parameters, such as size and 
porosity. The size of the NPs determines the specific surface 
area of the drug, improving the rate of dissolution when the 
area increases. On the other hand, porosity is an important 
property because it determines, for example, the ability to 
trap gases in the NPs. This property can be used to control 
the release rate of the drug and to direct it to specific regions 
of the body. NPs can be used to deliver drugs through  
several administration routes and, for example, have been 
successfully proved to deliver intravenous drugs, ensuring 
safe passage through the smallest blood vessels in the body.   
 Undoubtedly, one of the greatest challenges in medicine 
is to combine emerging nanotechnology with cellular and 
molecular techniques in order to develop better diagnostics 
and drug delivery systems to treat diseases such as cancer.  
 CS was introduced as a potential gene carrier in 1995 and 
various nanosystems based on CS and derivatives have been 
investigated, including unmodified CS with different MW 
and DD, quaternized CS, bile acid-modified CS, PEGylated 
CS, and CS bearing specific ligands [77]. CS-based nanode-
livery systems have been extensively studied for organ-
specific applications (e.g., for colon, kidney, lung, and liver) 
[16]. 
 An interesting approach was carried out by Li et al. [78], 
who designed CS-based multifunctional nanocarriers modi-
fied by L-valine, used as a target ligand to facilitate the ab-
sorption of the small intestine, and phenylboronic acid, used 
as a glucose-responsive unit, to overcome multiple barriers 
associated to the oral delivery of insulin. The results showed 
that the nanocarriers exhibited low toxicity and excellent 
stability in the protein solution. Moreover, the nanocarriers 
presented protective properties for insulin against enzymatic 
degradation. After oral administration to diabetic rats, the 
insulin-loaded nanocarriers exhibited an obvious hypogly-
cemic effect and, in addition, higher serum insulin level 
could be obtained after post-administration and maintained a 
higher level for a longer time. All these results suggested that 
insulin-loaded CS-based nanocarriers have a potential appli-
cation in diabetes treatment via oral ingestion. 
4.3. CS-based Systems for Gene Delivery 
 In recent years, the appearance of gene therapy as an 
emerging trend in medicine has been evident due to its great 
therapeutic potential to develop curative treatments for nu-
merous diseases of genetic origin. Gene therapy is based on 
the transfer of genetic material to specific cells of the body to 
regulate the expression of certain proteins. However, the 
systemic delivery of naked therapeutic genes is unrealistic 
because of their non-specificity toward target cells, rapid 
clearance by the mononuclear phagocyte system, and  
vulnerability to nuclease degradation [79]. Additionally, the 
large size, hydrophilic nature, and high anionic charge den-
sity can also hinder intracellular delivery of the naked gene 
[80]. Thus, the main challenge of gene therapy in human 
medicine is the development of gene delivery vectors, in 
order to help the process of transfer of the therapeutic gene 
to the target cells to be carried out safely and efficiently. 
This has motivated researchers to look for potential alterna-
tives for gene transfer vectors. In general, vectors are classi-
fied into two groups: viral and non-viral. According to this 
classification, the polymeric systems of genes delivery are 
included in the category of non-viral vectors. A non-viral 
vector must not only allow reaching the target action site in 
order to achieve a local or systemic effect, but must also fa-
cilitate intracellular uptake and improve the intracellular 
traffic of the nucleic acid payload. CS is one of the most 
promising among natural polymer-based gene delivery vec-
tors, due to its biodegradability, biocompatibility, and degra-
dation potential [81]. Its role in gene delivery is supported by 
its ability to protonate in acidic solution and to form a com-
plex with DNA through electrostatic interactions [82]. The 
stability and transfection efficiency of CS/DNA polyplexes 
are strongly influenced by various formulation parameters, 
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which include MW and DD of CS, stoichiometry or N/P 
ratio of the CS/DNA polyplex (charge ratio of amines of CS 
to phosphates of DNA), pH of the transfection medium, se-
rum concentration, and cell types [83, 84]. The modification 
of these parameters can significantly influence particle size, 
surface charge, stability, cellular uptake, and dissociation of 
CS/DNA polyplex, and hence the overall gene transfection 
efficiency. Therefore, these parameters must be considered 
carefully while designing CS-based gene delivery vectors. 
 In 1995, CS was first described as a delivery system for 
plasmids by Mumper et al. [77]. One of the major challenges 
in gene delivery is to protect DNA from nuclease action. The 
cationic charge of CS is found to be very useful to interact 
ionically with negatively charged DNA, thereby protecting 
the DNA against nuclease activity [85]. CS/DNA NPs may 
be readily formed by coacervation between the positively 
charged amine groups on CS and negatively charged phos-
phate groups on DNA.  
 In an interesting study performed by Amaduzzi et al. 
[86], the observed aggregation behavior of CS/DNA com-
plexes was compared with the predictions of existing models 
for the complexation of oppositely charged polyelectrolytes. 
CS/DNA complexes were prepared at different charge ratios 
and CS MW and their structure was characterized using dif-
ferent and complementary microscopy approaches, light 
scattering and electrophoretic mobility techniques. Distinc-
tive “tadpole-like” aggregates were observed when the poly-
cation was in excess, whereas only globular aggregates were 
found in excess of DNA. Close to the isoelectric point, elon-
gated fiber-like structures appeared. With regard to the  
models discussed, different apparently uncorrelated observa-
tions reported in the literature found a systematic interpreta-
tion, concluding that these models are useful tools to guide 
the design of new and more efficient polycation-based vec-
tors for more effective gene delivery. 
 Boonthum et al. [87] synthesized a gonadotropin-
releasing hormone-conjugated CS (GnRH-CS) as a potential 
vector for gene delivery. They found that the GnRH-CS spe-
cifically delivered plasmid DNA to targeted cells and  
exhibited higher transfection activity compared to unmodi-
fied CS. They concluded that GnRH-CS could be a promi-
sing carrier for targeted DNA delivery to GnRHR-expressing 
cells. 
 Other study performed by Lee et al. [88] describes the 
synthesis of glycol CS–methyl acrylate-polyethylenimine 
(GMP) for use as a non-viral vector system. The obtained 
materials were in vitro evaluated for application as gene de-
livery vehicles, showing low cytotoxicity and high transfec-
tion efficiency. The results allowed the authors concluding 
that GMP polymer could be appropriate for non-viral gene 
delivery vector. 
4.4. CS-based Systems in Cancer Therapy 
 Therapeutics against cancer is an area that requires 
continuous improvement of the drugs to achieve greater 
therapeutic efficacy and reduce side-effects to minimum 
thresholds. Chemotherapy is based mainly on the use of al-
kylating agents, antimetabolites, anthracyclines, alkanoids 
and terpenoids, and is generally administered by intravenous 
injection. There are two groups of substances which are used 
for anticancer pharmacotherapy: small cytostatic drugs like 
carboplatin, doxorubicin, and 5-fluorouracil (5-FU), and 
nucleic acid- or peptide-based actives. Although all of these 
substances are highly effective in vitro when applied directly 
to cell cultures, their clinical use and their therapeutic effi-
cacy are limited by either severe side effects or insufficient 
bioavailability. Nevertheless, the main challenge is that most 
of the chemotherapeutic agents lack an intrinsic specificity 
for the malignant cells, affecting other normal cells. In addi-
tion, many of these drugs have poor aqueous solubility or 
cannot reach tumor tissue due to cellular mechanisms  
causing drugs resistance. For this reason, effective polymeric 
drug carriers are needed to overcome these drawbacks.  
 In this context, CS has been frequently used as an exci-
pient in such systems and proved to be an excellent  
alternative. In addition, CS is recognized as a substance that 
helps improve the cellular uptake and tissue penetration of 
different active agents. Furthermore, this biopolymer has 
various biological effects by itself, such as antimicrobial 
activity, stimulation of the immune system and even some 
activity against cancer, since it can modify tumor growth, 
what gives an additional value to its use as a promising ex-
cipient for specific therapeutic strategies. Various researches 
demonstrate the beneficial effect of CS in the transport of 
chemotherapeutic drugs, such as doxorubicin and cisplatin 
[89, 90]. CS also stands out for its versatility, since in a drug 
delivery system it can be used as an oligo or polymer, as a 
polymer-drug complex, and as a material for the formation 
of hydrogel or for the production of micro or nanoparticles. 
CS properties can be easily modulated by chemical modifi-
cations through the amino groups, using, for example, side 
carbon chains or functional groups.  CS-based carrier sys-
tems can accumulate inside the malignant tissue, due to the 
so-called enhanced permeability and retention effect, caused 
by leaky blood vessel endothelia in the tumor. Thus, the side 
effects of the active agents in healthy tissues are reduced 
while the drug concentration on the site of action is in-
creased. CS formulations enable anticancer drugs to over-
come their biopharmaceutical inadequateness and enhance 
their biological activity.  
 Nanotechnology has allowed great advances in the detec-
tion and treatment of cancer. As current technologies are 
refined and improved, the side effects inherent in cancer 
treatment will diminish, allowing patients to have a better 
life quality and longer survival. Similarly, it can be predicted 
that there will be notable advances in the development of 
CS-based NP delivery systems for the treatment of different 
human diseases, with special emphasis on the treatment of 
cancer. Therefore, this biopolymer can play a key role in the 
investigation of new therapeutic strategies and offers va-
luable advantages in the development of carrier systems for 
application in local and systemic therapy against cancer. Tan 
et al. [91] published a review article about CS-based delivery 
systems of doxorubicin for cancer therapy. They summarized 
different methods for the drug encapsulation to deliver it in 
the specific lesion site, which allowed reducing side-effects. 
 Recently, Poloxamer surface modified trimethyl CS NPs 
were prepared by Li et al. [92] for the delivery of 
methotrexate (MTX) in osteosarcoma. The results indicated 
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that the NPs presented higher cytotoxicity in MG63 cells 
than the free MTX, explained by its enhanced cellular uptake 
through energy-dependent endocytosis process. Furthermore, 
the apoptosis effect was also increased in comparison to that 
of free drug, with bright chromatin condensation and nuclear 
fragmentation. 
 On the other hand, Rudzinski et al. [93] encapsulated 
anti-β-catenin small interfering RNA in CS and PEG-grafted 
CS NPs, for transfection into colon cancer cells. They found 
a decrease in β-catenin protein levels in cultured colon can-
cer cells for both CS and PEG-grafted CS NPs. 
5. FUTURE TRENDS 
 Over the last few years, scientific databases reveal that 
there are thousands of articles and patents related to chitin 
and CS-based materials for biomedical applications. As CS 
biodegradable properties, low immunogenicity, bioactivity 
and enhanced biocompatibility, it can be considered the first-
choice polymer to be employed in the biomedical area.  
 Probably, the most promising medical application that 
should be emphasized is its use in drug delivery systems. 
Since CS and derivatives systems allow higher drug loads, 
they are able to modulate the drug release, and matrices with 
different degradation kinetics can be designed. In addition, 
CS-based formulations could be designed to respond to ex-
ternal stimuli, which make it possible to produce intelligent 
and effective drug delivery systems. 
 Other applications that remain to be explored in depth are 
the possibility of linking CS, through covalent or ionic 
bonds, to proteins and peptides in scaffolds for tissue  
regeneration, and as carriers in the administration of genes, 
due to the cationic nature of CS and its ability to form 
chelates with DNA. 
 In most of the biomedical applications mentioned, a 
preclinical and clinical test of the designed systems were not 
carried out, which is fundamental for their application as 
new devices in clinical therapy. 
 Future efforts should focus on other important aspects. 
On one hand, the research and development of CS and de-
rivatives with improved solubility must continue. Precisely, 
its low solubility is what restricts many applications of  
this biomaterial. On the other hand, since the MW, DD,  
polymerization degree and obtaining source govern CS be-
havior, it is necessary to standardize the production methods 
to guarantee reproducibility of CS physicochemical charac-
teristics among batches. For this reason, optimizing the  
processes of isolation and purification of CS to improve pu-
rity and reproducibility according to international Pharma-
copoeias will be critical for the commercial success of CS-
based formulations. Biotechnological processes or genetic 
engineering methods, focused on producing a material with 
previously designed characteristics, are some alternatives to 
those currently obtained from natural marine sources.  
CONCLUSION 
 Numerous developments have been reported on CS de-
rivatives with promising properties, such as better solubility, 
stronger mucoadhesive capacities, and inhibitory enzymatic 
properties. The qualities of CS related to the improvement of 
the permeation, its mucoadhesive properties, as well as the 
controlled release of drugs and the ability to open tight  
junctions, allow to conclude that this biopolymer will be an 
excellent tool for the development of systems for peptide 
delivery. Certainly, these properties can be further improved 
by simple chemical modifications in their primary amino 
group. These unique qualities make CS and, in particular, its 
derivatives, valuable excipients for the development of drug 
delivery systems for the treatment of various human pa-
thologies and other applications. Despite all the qualities of 
this polymer, there are only few CS-based products in the 
market, so it is a priority to enhance the research to develop 
new technologies and CS-based systems to enforce this bio-
polymer in the industry. 
LIST OF ABBREVIATIONS 
5-FU = 5-fluorouracil 
CS = Chitosan 
DD = Deacetylation Degree 
DNA = Deoxyribonucleic Acid 
FDA = Food and Drug Administration 
GI = Gastrointestinal 
GMP = CS–methyl Acrylate-polyethylenimine  
GnRH = Gonadotropin-releasing Hormone 
KCSS = Kollicoal 
LT = Ludiflash®  
MT = Microcrystalline Cellulose 
MTX = Methotrexate 
MW = Molecular Weight 
NP = Nanoparticle 
PEG = Polyethylene Glycol 
PVA = Polyvinyl Alcohol 
QUR = Quercetin 
RES = Resveratrol 
RF = Radio Frequency 
RNA = Ribonucleic Acid 
TMC = N-trimethyl Chitosan 
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